PDCD1 and metastatic melanoma: However, there is also the sobering realization that besides combined therapies (CTLA-4 and PD-1 mAbs) in patients with metastatic melanoma, the majority of patients with other malignancies do not respond, experience serious side effects [24], or have tumors that are less amendable to treatment with immunotherapy.